Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support

B. Meisenberg, M. Lassiter, A. Hussein, M. Ross, J. J. Vredenburgh, W. P. Peters

Research output: Contribution to journalArticle

Abstract

High-dose cyclophosphamide (CY) is associated with a high risk of hemorrhagic cystitis. The reported frequency ranges from 6.5 to 52% despite the use of hydration protocols. The current study reports a hyperhydration and continuous bladder irrigation protocol which resulted in a very low incidence of microscopic hematuria and no reported cases of visible hematuria. Patients received baseline fluids at 200 ml/m2/h during chemotherapy. Additional fluid boluses were given if urine output fell below 200 ml/h. Bladder irrigation was performed at a rate of 1 l/h during and for 24 h after high-dose CY. Three hundred three evaluable patients with solid tumors received high-dose chemotherapy with CY at a dose of 5625 mg/m2 over 3 days. Patients also received cisplatin 165 mg/m2 and carmustine 600 mg/m2. Some patients received thiotepa 300-750 mg/m2 instead of carmustine. The overall incidence of microscopic hematuria (> 15 RBCs per high power field) was 19%, with only 11% of patients experiencing more than 50 RBCs per high power field. No patient developed visible hematuria or symptomatic hematuria requiring intervention. These results using aggressive hyperhydration and high volumes of continuous bladder irrigation are among the best reported following high-dose CY chemotherapy.

Original languageEnglish (US)
Pages (from-to)287-291
Number of pages5
JournalBone Marrow Transplantation
Volume14
Issue number2
StatePublished - 1994
Externally publishedYes

Fingerprint

Cystitis
Alkylating Agents
Hematuria
Bone Marrow
Drug Therapy
Cyclophosphamide
Carmustine
Urinary Bladder
Thiotepa
Incidence
Cisplatin
Urine
Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Meisenberg, B., Lassiter, M., Hussein, A., Ross, M., Vredenburgh, J. J., & Peters, W. P. (1994). Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplantation, 14(2), 287-291.

Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. / Meisenberg, B.; Lassiter, M.; Hussein, A.; Ross, M.; Vredenburgh, J. J.; Peters, W. P.

In: Bone Marrow Transplantation, Vol. 14, No. 2, 1994, p. 287-291.

Research output: Contribution to journalArticle

Meisenberg, B, Lassiter, M, Hussein, A, Ross, M, Vredenburgh, JJ & Peters, WP 1994, 'Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support', Bone Marrow Transplantation, vol. 14, no. 2, pp. 287-291.
Meisenberg B, Lassiter M, Hussein A, Ross M, Vredenburgh JJ, Peters WP. Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplantation. 1994;14(2):287-291.
Meisenberg, B. ; Lassiter, M. ; Hussein, A. ; Ross, M. ; Vredenburgh, J. J. ; Peters, W. P. / Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. In: Bone Marrow Transplantation. 1994 ; Vol. 14, No. 2. pp. 287-291.
@article{61dc2450c29e4b58b5ecf3b633f8491d,
title = "Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support",
abstract = "High-dose cyclophosphamide (CY) is associated with a high risk of hemorrhagic cystitis. The reported frequency ranges from 6.5 to 52{\%} despite the use of hydration protocols. The current study reports a hyperhydration and continuous bladder irrigation protocol which resulted in a very low incidence of microscopic hematuria and no reported cases of visible hematuria. Patients received baseline fluids at 200 ml/m2/h during chemotherapy. Additional fluid boluses were given if urine output fell below 200 ml/h. Bladder irrigation was performed at a rate of 1 l/h during and for 24 h after high-dose CY. Three hundred three evaluable patients with solid tumors received high-dose chemotherapy with CY at a dose of 5625 mg/m2 over 3 days. Patients also received cisplatin 165 mg/m2 and carmustine 600 mg/m2. Some patients received thiotepa 300-750 mg/m2 instead of carmustine. The overall incidence of microscopic hematuria (> 15 RBCs per high power field) was 19{\%}, with only 11{\%} of patients experiencing more than 50 RBCs per high power field. No patient developed visible hematuria or symptomatic hematuria requiring intervention. These results using aggressive hyperhydration and high volumes of continuous bladder irrigation are among the best reported following high-dose CY chemotherapy.",
author = "B. Meisenberg and M. Lassiter and A. Hussein and M. Ross and Vredenburgh, {J. J.} and Peters, {W. P.}",
year = "1994",
language = "English (US)",
volume = "14",
pages = "287--291",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support

AU - Meisenberg, B.

AU - Lassiter, M.

AU - Hussein, A.

AU - Ross, M.

AU - Vredenburgh, J. J.

AU - Peters, W. P.

PY - 1994

Y1 - 1994

N2 - High-dose cyclophosphamide (CY) is associated with a high risk of hemorrhagic cystitis. The reported frequency ranges from 6.5 to 52% despite the use of hydration protocols. The current study reports a hyperhydration and continuous bladder irrigation protocol which resulted in a very low incidence of microscopic hematuria and no reported cases of visible hematuria. Patients received baseline fluids at 200 ml/m2/h during chemotherapy. Additional fluid boluses were given if urine output fell below 200 ml/h. Bladder irrigation was performed at a rate of 1 l/h during and for 24 h after high-dose CY. Three hundred three evaluable patients with solid tumors received high-dose chemotherapy with CY at a dose of 5625 mg/m2 over 3 days. Patients also received cisplatin 165 mg/m2 and carmustine 600 mg/m2. Some patients received thiotepa 300-750 mg/m2 instead of carmustine. The overall incidence of microscopic hematuria (> 15 RBCs per high power field) was 19%, with only 11% of patients experiencing more than 50 RBCs per high power field. No patient developed visible hematuria or symptomatic hematuria requiring intervention. These results using aggressive hyperhydration and high volumes of continuous bladder irrigation are among the best reported following high-dose CY chemotherapy.

AB - High-dose cyclophosphamide (CY) is associated with a high risk of hemorrhagic cystitis. The reported frequency ranges from 6.5 to 52% despite the use of hydration protocols. The current study reports a hyperhydration and continuous bladder irrigation protocol which resulted in a very low incidence of microscopic hematuria and no reported cases of visible hematuria. Patients received baseline fluids at 200 ml/m2/h during chemotherapy. Additional fluid boluses were given if urine output fell below 200 ml/h. Bladder irrigation was performed at a rate of 1 l/h during and for 24 h after high-dose CY. Three hundred three evaluable patients with solid tumors received high-dose chemotherapy with CY at a dose of 5625 mg/m2 over 3 days. Patients also received cisplatin 165 mg/m2 and carmustine 600 mg/m2. Some patients received thiotepa 300-750 mg/m2 instead of carmustine. The overall incidence of microscopic hematuria (> 15 RBCs per high power field) was 19%, with only 11% of patients experiencing more than 50 RBCs per high power field. No patient developed visible hematuria or symptomatic hematuria requiring intervention. These results using aggressive hyperhydration and high volumes of continuous bladder irrigation are among the best reported following high-dose CY chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0028108127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028108127&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 287

EP - 291

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -